DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jim Cramer - 6 Jim - 6 Eli Lilly Eli Lilly - 6 Jim Cramer's - 6 Eli Lilly - 5 Lilly's - 3 it's - 2 — - 2
Top related locs:
U.S Novo NBCUniversal China Maxx New York City 30,2022 30,2022 . Virginia
Top related orgs:
CNBC - 6 Club - 3 Caterpillar - 3 Novo Nordisk - 3 Nasdaq - 2 Getty - 2 Company - 2 American Diabetes Association - 2

Search resuls for: "Eli Lilly Eli Lilly"


8 mentions found


☆ Why investors should buy these fixer-upper names, while sticking with 3 that are set to soar
  + stars: | 2023-10-11 | by ( Morgan Chittum | ) www.cnbc.com   time to read: +6 min
Oracle Oracle (ORCL) stock has been sliding for some time, with shares down 14% over the past month, even as the stock has climbed more than 33% this year. He added that this is a great level at which to buy Oracle stock. And here are three Club names that need no work, and are well-positioned to soar: Caterpillar Caterpillar (CAT) has weathered the market's volatility well. TJX Companies This is TJX Companies ' (TJX) time to shine, as the off-price retailer has the best business model to capture the spending of a cash-strapped consumer. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Jim Cramer, Walt Disney, Jim, Disney's, Nelson Peltz, Laxman Narasimhan, There's, Larry, Ellison, it's, we're, TJX, Eli Lilly Eli Lilly, Mounjaro —, Jim Cramer's, Angela Weiss Organizations: Nasdaq, Treasury, Club, Disney, Walt, ESPN, Comcast, Hulu, CNBC, Starbucks, U.S, Oracle Oracle, Oracle, Caterpillar Caterpillar, Caterpillar, Traders, New York Stock Exchange, AFP, Getty Locations: NBCUniversal, China, U.S, Maxx, New York City
☆ These are the top 5 performing Club stocks from mid-July to our August Monthly Meeting
  + stars: | 2023-08-17 | by ( Morgan Chittum | ) www.cnbc.com   time to read: +4 min
Humana Humana (HUM) is up 16.36% since the July meeting, the Club's second-best performing name over the roughly five-week period. Jim said during the August Monthly Meeting on Thursday that he's not as enamored with this stock recently. HUM mountain 2023-08-16 Humana (HUM) performance 3. PXD mountain 2023-08-16 Pioneer Natural Resources (PXD) performance 4. GOOGL mountain 2023-08-16 Alphabet Inc. Class A (GOOGL) performance (Jim Cramer's Charitable Trust is long LLY, HUM, PXD, CAT, GOOGL.
Persons: That's, Thursday's, Eli Lilly Eli Lilly, Eli Lilly, Lilly's, Jim Cramer, LLY, Jim, he's, PXD, GOOGL, Jim Cramer's, 30,2022 . Virginia Sherwood Organizations: CNBC, Wall Street, Company, Natural Resources, Club, Caterpillar, CAT, Big Tech, Inc, NYSE, 30,2022 . Locations: 30,2022, 30,2022 . Virginia
☆ We are buying one health-care stock and raising our price target on another
  + stars: | 2023-08-09 | by ( Jim Cramer | ) www.cnbc.com   time to read: +3 min
We are buying 100 shares of GE Healthcare Technologies (GEHC) at roughly $73.76. Following the trade, Jim Cramer's Charitable Trust will own 850 shares of GEHC, increasing its weighting in the portfolio to 2.16% from 1.91%. The medical device group has been in a steady decline lately as the aversion to health-care stocks this year continues, and we are using this weakness to buy a little more of GE Healthcare. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer's, —, Peter Arduini, Eli Lilly Eli Lilly, Lilly, Eli Lilly, Jim Cramer, Jim, Jim Cramer Rob Kim Organizations: GE Healthcare Technologies, GEHC, GE Healthcare, GE, Novo Nordisk, Jefferies, pharma, CNBC Locations: Lilly
☆ Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
  + stars: | 2023-06-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +10 min
The company's chief rival, Denmark-based Novo Nordisk (NVO), also published promising data on drugs in its pipeline, including its own oral weight-loss treatment. Other pharmaceutical companies are racing to compete with Novo Nordisk and Eli Lilly, including Amgen (AMGN) and Pfizer (PFE). Barclays on Tuesday projected Eli Lilly's three leading obesity-and-diabetes drugs could generate nearly $49 billion in combined sales in 2030. Eli Lilly Eli Lilly has multiple drugs in development that fall under the GLP-1 umbrella in various stages of clinical development. Novo Nordisk Novo Nordisk currently dominates the market for GLP-1 drugs, with three products in the class on the U.S. market already: Ozempic, Wegovy and Rybelsus.
Persons: It's, Eli Lilly, Eli Lilly's, retatrutide, Lilly, there's, Lilly's, Geoff Meacham, Eli Lilly Eli Lilly, Jim Cramer, Evan David Seigerman, —, — Morgan Stanley, Wegovy, Rybelsus, Jim Cramer's, Jim, Mike Segar Organizations: Club, Novo Nordisk, New England, of Medicine, American Diabetes Association, Pfizer, Reuters, Barclays, Bank of America, CNBC, JPMorgan, Drug Administration, Equity, BMO Capital, Novo Nordisk Novo Nordisk, GLP, FDA, Nordisk, Company Locations: San Diego, Denmark, GLP, It's, Novo, Novo Nordisk's, Branchburg , New Jersey
☆ Drug trial results could boost 2 Club pharma stocks. Here's what to expect
  + stars: | 2023-06-12 | by ( Kevin Stankiewicz Jeff Marks | Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.
Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana
☆ 'I think we have to let it run,' Cramer says of this industrial powerhouse
  + stars: | 2023-06-07 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +3 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Watch Eli Lilly Eli Lilly (LLY) is set to present data on its earlier-stage diabetes-and-obesity drugs in the coming weeks, offering another potential upside catalyst for a stock that's already climbed nearly 40% over the past three months. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Caterpillar Watch Eli Lilly, Jim, Eli Lilly Eli Lilly, it's, Eli Lilly, Jim Cramer's Organizations: CNBC, Caterpillar Watch, Nasdaq, Meta, Microsoft, Nvidia, Caterpillar Construction, Caterpillar, Diabetes
☆ Jim Cramer's Investing Club meeting Tuesday: Inflation cools, stock trim, Eli Lilly
  + stars: | 2022-12-13 | by ( Krystal Hur | ) www.cnbc.com   time to read: +2 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Wait to buy Eli Lilly Eli Lilly (LLY) said Tuesday it expects 2023 revenue to grow ahead of Wall Street expectations. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
☆ What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly
  + stars: | 2022-11-30 | by ( ) www.cnbc.com   time to read: +6 min
Donanemab is the name of Eli Lilly's Alzheimer's drug in its own late-stage trials. JPMorgan has a neutral (hold) rating on Biogen shares and an overweight (buy) rating on Eli Lilly shares. What it means for Eli Lilly Eli Lilly has a phase three trial underway for its donanemab Alzheimer's drug that is similar to lecanemab, which is why the Biogen-Eisai data has been interpreted as favorable for the Club holding. Clumps of the protein, known as amyloid plaques, are one of the key markers of Alzheimer's disease. Previous drugs developed around the a-beta hypothesis — including those from Eli Lilly — have failed to meaningfully delay the disease's progression.
0 next >>
Total: 8